The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
Open accessAbstract
Recent studies have shown that mutations at amino-acid 482 in the ABCG2 gene affect the substrate specificity of the protein. To delineate the effects of these mutations clearly, human embryonic kidney cells (HEK-293) were stably transfected with wild-type 482R or mutant 482G and 482T ABCG2. By flow cytometry, mitoxantrone, BODIPY-prazosin, and Hoechst 33342 were found to be substrates of all ABCG2 proteins, while rhodamine 123, daunorubicin, and LysoTracker Green were transported only by mutant ABCG2. In cytotoxicity assays, all ABCG2 proteins conferred high levels of resistance to mitoxantrone, SN-38, and topotecan, while mutant ABCG2 also exhibited a gain of function for mitoxantrone as they conferred a four-fold greater resistance compared to wild type. Cells transfected with mutant ABCG2 were 13- to 71- fold resistant to the P-glycoprotein substrates doxorubicin, daunorubicin, epirubicin, bisantrene, and rhodamine 123 compared to cells transfected with wild-type ABCG2, which were only three- to four-fold resistant to these compounds. ABCG2 did not confer appreciable resistance to etoposide, taxol or the histone deacetylase inhibitor depsipeptide. None of the transfected cell lines demonstrated resistance to flavopiridol despite our previous observation that ABCG2-overexpressing cell lines are cross-resistant to the drug. Recently reported inhibitors of ABCG2 were evaluated and 50 microM novobiocin was found to reverse wild-type ABCG2 completely, but only reverse mutant ABCG2 partially. The studies presented here serve to underscore the importance of amino-acid 482 in defining the substrate specificity of the ABCG2 protein and raise the possibility that amino-acid 482 mutations in human cancers could affect the clinical application of antagonists for ABCG2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Miyake, K., Mickley, L. A., Litman, T., Zhan, Z., Robey, R. W., Cristensen, B., Brangi, M., Greenberger, L., Dean, M. C., Fojo, T., et al. (1999) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 929
Self-citationAllikmets, R., Schriml, L. M., Hutchinson, A. A., Romano-Spica, V., & Dean, M. C. (1998) · PubMed · Cited by 918
Scharenberg, C. W., Harkey, M. A., & Torok-Storb, B. (2002) · Blood · doi:10.1182/blood.v99.2.507 · Cited by 770
Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538
Self-citationRabindran, S. K., Ross, D. D., Doyle, L. A., Yang, W., & Greenberger, L. M. (2000) · PubMed · Cited by 487
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp, M. C., Floot, B. G., & Schellens, J. H. M. (1999) · PubMed · Cited by 487
Honjo, Y., Hrycyna, C. A., Yan, Q. W., Medina-Pérez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean, M. C., & Bates, S. E. (2001) · PubMed · Cited by 429
Self-citationKim, M., Turnquist, H. R., Jackson, J. D., Sgagias, M. K., Yan, Y., Gong, M., Dean, M. C., Sharp, J. G., & Cowan, K. H. (2002) · PubMed · Cited by 397
Allen, J. D., Brinkhuis, R. F., Wijnholds, J., & Schinkel, A. H. (1999) · PubMed · Cited by 353
Robey, R. W., Medina-Pérez, W. Y., Nishiyama, K., Lahusen, T. J., Miyake, K., Litman, T., Senderowicz, A. M., Ross, D. D., & Bates, S. E. (2001) · PubMed · Cited by 341
Self-citationRabindran, S. K., He, H., Singh, M. S., Brown, E., Collins, K., Annable, T., & Greenberger, L. M. (1998) · PubMed · Cited by 305
Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C. H. M., Robey, R. W., Pommier, Y. G., Fojo, T., & Bates, S. E. (1999) · PubMed · Cited by 263
Self-citationOverexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Volk, E. L., Farley, K. M., Wu, Y. F., Li, F., Robey, R. W., & Schneider, E. (2002) · PubMed · Cited by 248
Self-citationA functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)
Robey, R. W., Honjo, Y., van de Laar, A., Miyake, K., Regis, J. T., Litman, T., & Bates, S. E. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00308-x · Cited by 245
Self-citationBreast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells
Kawabata, S., Oka, M., Shiozawa, K., Tsukamoto, K., Nakatomi, K., Soda, H., Fukuda, M., Ikegami, Y., Sugahara, K., Yamada, Y., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4267 · Cited by 242
Chen, Y. N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J. L., & Fojo, A. T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38781-2 · Cited by 221
Allen, J. D., Jackson, S. C., & Schinkel, A. H. (2002) · PubMed · Cited by 151
Stride, B. D., Grant, C. E., Loe, D. W., Hipfner, D. R., Cole, S. P. C., & Deeley, R. G. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.3.344 · Cited by 145
Wang, X., Furukawa, T., Nitanda, T., Okamoto, M., Sugimoto, Y., Akiyama, S.-I., & Baba, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.1.65 · Cited by 142
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells
Yang, C.-H., Schneider, E., Kuo, M., Volk, E. L., Rocchi, E., & Chen, Y. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00396-8 · Cited by 113
Chen, K. G., Durán, G. E., Steger, K. A., Lacayo, N. J., Jaffrézou, J., Dumontet, C., & Sikic, B. I. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5974 · Cited by 81
Ramı́rez, J., Iyer, L., Journault, K., Bélanger, P., Innocenti, F., Ratain, M. J., & Guillemette, C. (2002) · Pharmaceutical Research · doi:10.1023/a:1015341726183 · Cited by 46
Feng, J., Grant, G., & Melera, P. W. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.922 · Cited by 31
Cited by
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Robey, R. W., To, K. K. K., Polgar, O., Dohse, M., Fetsch, P., Dean, M., & Bates, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.003 · Cited by 449
Self-citationBurger, H., van Tol, H., Boersma, A. W. M., Brok, M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2004) · Blood · doi:10.1182/blood-2004-04-1398 · Cited by 417
Role of the breast cancer resistance protein (ABCG2) in drug transport
Mao, Q. (2005) · The AAPS Journal · doi:10.1208/aapsj070112 · Cited by 405
Metadata
- Authors
- Robey, R. W., Honjo, Y., Morisaki, K., Nadjem, T. A., Runge, S., Risbood, M., Poruchynsky, M. S., & Bates, S. E.
- Venue
- British Journal of Cancer
- Published
- 2003-11
- Volume
- 89
- Issue
- 10
- Pages
- 1971-1978
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2082843436
- Cited by
- 368
- References
- 27
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.